Scarica l'app Stockscreener
3.36
8.74%
0.27
Dopo l'orario di chiusura:
3.32
-0.04
-1.19%
Precedente Chiudi:
$3.09
Aprire:
$3.13
Volume 24 ore:
1.77M
Relative Volume:
1.16
Capitalizzazione di mercato:
$308.71M
Reddito:
-
Utile/perdita netta:
$-26.44M
Rapporto P/E:
-12.00
EPS:
-0.2799
Flusso di cassa netto:
$-22.38M
1 W Prestazione:
+7.69%
1M Prestazione:
+46.09%
6M Prestazione:
+302.40%
1 anno Prestazione:
+414.08%
Intervallo 1D:
$3.11
$3.44
Intervallo di 1 settimana:
$2.71
$3.44
Portata 52W:
$0.49
$3.44
Context Therapeutics Inc Stock (CNTX) Company Profile
Nome
Context Therapeutics Inc
Settore
Industria
Telefono
267-225-7416
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
3.36 | 308.71M | 0 | -26.44M | -22.38M | -0.2799 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-11-25 | Iniziato | D. Boral Capital | Buy |
| 2024-05-16 | Iniziato | Piper Sandler | Overweight |
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data - Yahoo Finance
Context Therapeutics Inc. Files 8-K and Certificate of Correction to Amended and Restated Certificate of Incorporation (March 11, 2026) - Minichart
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes - TipRanks
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Quarterly Earnings: How does Context Therapeutics Inc compare to its peersWeekly Profit Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Context Therapeutics (CNTX) to Release Earnings on Thursday - MarketBeat
Movement Recap: Can Context Therapeutics Inc stock double in the next yearPortfolio Update Report & Stock Market Timing Techniques - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market Expected - openPR.com
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Context Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ADXN.SW Addex Therapeutics Ltd (SIX) 09 Mar 2026: Earnings due; liquidity and forecast to watch - Meyka
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference - Yahoo Finance
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - Sahm
New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy - Cantech Letter
CNTX SEC FilingsContext Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
CNTX: Advancing three T-cell engager programs in solid tumors with key data milestones ahead - TradingView
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CNTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - The Globe and Mail
CNTX Should I Buy - Intellectia AI
Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World
Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy" - MarketBeat
Context-dependent translation inhibition as a cancer therapeutic modality - Nature
Context Therapeutics (CNTX) awards 270,000 stock options to Chief Legal Officer - Stock Titan
CFO at Context Therapeutics (CNTX) receives 275,000-share stock option grant - Stock Titan
Context Therapeutics (CNTX) CEO granted 815,000 stock options - Stock Titan
What is Context Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Target Return Focused Stock Picks - mfd.ru
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN
Is Context Therapeutics Inc. a potential multi bagger2025 Technical Patterns & Smart Money Movement Tracker - mfd.ru
Shorts Report: Is H2O America stock forming a triangle patternQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Geopolitics Watch: Whats the fair value of TMHC stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Profit Recap: What is Context Therapeutics Incs book value per shareJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Fund Flows: How does Context Therapeutics Inc perform in inflationary periodsEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Great Point reveals 5.1% Context Therapeutics (CNTX) stake in 13G/A - Stock Titan
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
Earnings Report: Is Klaviyo Inc attractive for institutional investorsLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
How cyclical is Context Therapeutics Inc.’s revenue streamProfit Target & Real-Time Buy Signal Notifications - mfd.ru
Bank Watch: Does ABRPRD have pricing powerPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru
Context Therapeutics Inc Azioni (CNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):